Immunic Shares Promising Data on Vidofludimus Calcium at ACTRIMS Forum 2025

Immunic, Inc. presented significant data on its leading drug candidate, Vidofludimus Calcium, at the ACTRIMS Forum 2025 in West Palm Beach, Florida. Vidofludimus Calcium activates the Nurr1 receptor, reducing neuronal loss and injury, which could prove beneficial in treating multiple sclerosis (MS).

The company shared preclinical findings and baseline characteristics from the phase 2 CALLIPER trial. This trial in progressive MS evaluates Vidofludimus Calcium's effects on a non-active PMS population, with top-line data expected in April. The drug's impact on 24-week disability progression is anticipated to reflect its influence on compartmentalized CNS pathology.

Overall, the data highlights Vidofludimus Calcium’s neuroprotective potential through decreasing microglial activation, with implications for the treatment of MS.